Asarina Pharma Phase IIB Study receives surge in applicants volunteering for new PMDD treatment—on its first day live
Stockholm – April 16, 2018. In just one day 29 patients passed the first screening stage of the trial for the world’s first PMDD therapy. Asarina Pharma CEO Peter Nordkild: “This reflects the desperate need for a dedicated therapy for this devastating form of PMS—and the huge market potential.”
The phase IIB study aims to recruit 225-250 patients in total from Sweden, UK, Germany and Poland. Successfully approving 29 patients to begin the trial process on the first day alone is significant, says Nordkild:
“4-5% of women of a fertile age suffer from PMDD today, and yet they’re mostly being offered no treatment, or SSRI anti-depressants, which produce their own negative side effects. Our trial product, Sepranolone, is a natural, endogenous compound that isn’t an anti-depressant or a hormone. It delivered 80% symptom relief In Phase IIA clinical trials, and we’re confident it can treat PMDD—and help millions of women take back control of their lives.”
Symptoms of PMDD, the severest form of PMS, include mood swings, rage, anxiety and depression, disrupting families, relationships and careers. The phase IIB study is a randomized, placebo-controlled, double-blind clinical study that will enrol 225-250 patients in Sweden, UK, Germany and Poland. The first four German trial clinics now running are in Berlin, Frankfurt, Schwerin and Essen (with Nurnberg soon to follow). In Poland, the clinical in Krakow has started (with Warsaw, Elblag and Katowice soon to follow) along with a site in Sweden-Stockholm. Three clinics in England will start soon-in London, Liverpool and Stoke on Trent.
If you want more information on the study go here.
For further information, please contact:
Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46, e-mail: email@example.com
Karin Ekberg, COO, Asarina Pharma AB
Phone: +46 70 45 800 45, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Asarina Pharma AB
Asarina Pharma AB is a Swedish biotech company focusing on the development of Sepranolone for the treatment of premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. The company’s primary goal is to offer a novel therapy that is specifically designed for PMDD. Asarina has a 2nd generation oral compound in preclinical development for PMDD. The principal shareholders in Asarina Pharma are Kurma Biofund I, Rosetta Capital IV LP, IDinvest Partners, the Foundation for Baltic and European Studies (Östersjöstiftelsen) and Ergomed Plc. For more information, please visit: www.asarinapharma.com